Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iben Spanggaard

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Cytotherapy|March 24, 2020
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcomeVinicius Araujo B de Lima, Annie Borch, Morten Hansen, et al.
Cancer Genetics|May 28, 2025
HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, RigshospitaletRosa Damkjær Britton, Daniela Alosi, Luca Robinson, et al.
Human Gene Therapy. Clinical Development|August 29, 2013
Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man studyIben Spanggaard, Marko Snoj, Andrea Cavalcanti, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2023
New pathogenic germline variants identified in mesotheliomaLaila Belcaid, Birgitte Bertelsen, Karin Wadt, et al.
The Oncologist|October 16, 2025
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 resultsIben Spanggaard, Marc Matrana, Caio Rocha Lima, et al.
Oncotarget|March 13, 2019
Application of cell-free DNA for genomic tumor profiling: a feasibility studyLise B Ahlborn, Kristoffer S Rohrberg, Migle Gabrielaite, et al.
British Journal of Cancer|December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumoursDebbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
JCO Precision Oncology|March 13, 2025
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid TumorsMartina Eriksen, Anne M Hansen, Annelaura B Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|December 19, 2022
Extensive genomic analysis in patients with <i>KRAS</i>-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impactIda Christine Jacobsen, Iben Spanggaard, Martin Højgaard, et al.
Nature Medicine|May 24, 2024
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trialJordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Cytotherapy|March 24, 2020
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcomeVinicius Araujo B de Lima, Annie Borch, Morten Hansen, et al.
Cancer Genetics|May 28, 2025
HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, RigshospitaletRosa Damkjær Britton, Daniela Alosi, Luca Robinson, et al.
Human Gene Therapy. Clinical Development|August 29, 2013
Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man studyIben Spanggaard, Marko Snoj, Andrea Cavalcanti, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2023
New pathogenic germline variants identified in mesotheliomaLaila Belcaid, Birgitte Bertelsen, Karin Wadt, et al.
The Oncologist|October 16, 2025
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 resultsIben Spanggaard, Marc Matrana, Caio Rocha Lima, et al.
Oncotarget|March 13, 2019
Application of cell-free DNA for genomic tumor profiling: a feasibility studyLise B Ahlborn, Kristoffer S Rohrberg, Migle Gabrielaite, et al.
British Journal of Cancer|December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumoursDebbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
JCO Precision Oncology|March 13, 2025
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid TumorsMartina Eriksen, Anne M Hansen, Annelaura B Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|December 19, 2022
Extensive genomic analysis in patients with <i>KRAS</i>-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impactIda Christine Jacobsen, Iben Spanggaard, Martin Højgaard, et al.
Nature Medicine|May 24, 2024
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trialJordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Pageof 4